share_log

Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS (Budesonide) Aerosol Foam to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS (Budesonide) Aerosol Foam to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bausch Health, Canada Inc.宣佈了用於治療成人輕度至中度遠端潰瘍性結腸炎的pruceris(布地奈德)氣溶膠泡沫的更多公共藥物計劃清單
Bausch Health ·  05/23 12:00

LAVAL, QC, May 23, 2024 - Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), today announced additional Canadian public drug plan listings for PrUCERIS (budesonide) aerosol foam to treat mild to moderate distal ulcerative colitis in adults.1

魁北克省拉瓦爾,2024年5月23日——加拿大鮑什健康公司,隸屬於鮑什健康公司(紐約證券交易所代碼:BHC)(多倫多證券交易所:BHC)(多倫多證券交易所: BHC),今天宣佈了更多用於治療成人輕度至中度遠端潰瘍性結腸炎的pruCeris(布地奈德)氣溶膠泡沫的加拿大公共藥物計劃清單。1

UCERIS has most recently become available for patients through the public drug plans of Alberta, Prince Edward Island and Newfoundland and Labrador, as well as to beneficiaries of the federal drug plans for Indigenous people through the Non-Insured Health Benefit (NIHB) and Veterans Affairs Canada.

最近,通過艾伯塔省、愛德華王子島和紐芬蘭及拉布拉多的公共藥物計劃向患者提供UCERIS,並通過非保險健康福利(NIHB)和加拿大退伍軍人事務部向針對土著人民的聯邦藥物計劃的受益人提供UCERIS。

Earlier this year, UCERIS was made available for patients through the public drug plans of Ontario, Quebec, Saskatchewan, New Brunswick and Nova Scotia.

今年早些時候,通過安大略省、魁北克省、薩斯喀徹溫省、新不倫瑞克省和新斯科舍省的公共藥物計劃,向患者提供了UCERIS。

"We are very pleased that these further public drug plan listings for UCERIS mean more Canadians with distal ulcerative colitis now have access to this new therapy," said Cees Heiman, Senior Vice-President, Europe and Canada, Bausch Health. "It is encouraging that these public drug plans have moved quickly to finalize their listings after our agreement in principle following negotiations with the pan-Canadian Pharmaceutical Alliance."

Bausch Health負責歐洲和加拿大的高級副總裁西斯·海曼說:“我們很高興這些針對UCERIS的更多公共藥物計劃清單意味着更多的加拿大遠端潰瘍性結腸炎患者現在可以獲得這種新療法。”“令人鼓舞的是,在我們與泛加拿大製藥聯盟進行談判後,原則上達成協議,這些公共藥物計劃已迅速完成上市。”

UCERIS, part of the Company's growing gastrointestinal franchise, has been available in Canada by prescription since September 2023 and is also covered by the majority of private insurance drug plans in Canada.

UCERIS是該公司不斷增長的胃腸道特許經營權的一部分,自2023年9月起在加拿大通過處方上市,加拿大大多數私人保險藥物計劃也涵蓋了UCERIS。

UCERIS is the only glucocorticosteroid rectal foam available in Canada indicated for the induction of remission in adult patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.1 In a study comparing budesonide foam and budesonide enema in patients with active distal ulcerative colitis, most patients (84%) preferred the foam formulation because of its better tolerability and easier application.2

UCERIS是加拿大唯一一款糖皮質激素直腸泡沫,適用於活動性輕度至中度遠端潰瘍性結腸炎的成年患者誘導緩解,延伸至****邊緣 40 cm。1 在一項比較活動性遠端潰瘍性結腸炎患者布地奈德泡沫和布地奈德灌腸的研究中,大多數患者(84%)更喜歡泡沫配方,因爲它的耐受性更好易用性和更簡便的應用。2

Ulcerative colitis is a chronic disease affecting the large intestine, or colon. The condition causes inflammation and ulceration (sores) along the lining of the colon, which can lead to abdominal pain, cramps, bleeding and diarrhea.3 In ulcerative colitis, the inflammation starts at the rectum and continues through the colon. Symptoms include diarrhea with blood and mucus, pain on the left-hand side of the abdomen, urgency and tenesmus (the feeling of needing to pass stools even if the bowel is empty).3

潰瘍性結腸炎是一種影響大腸或結腸的慢性疾病。這種情況會導致結腸內膜發炎和潰瘍(潰瘍),從而導致腹痛、絞痛、出血和腹瀉。3 在潰瘍性結腸炎中,炎症從直腸開始,一直持續到結腸。症狀包括帶血和粘液的腹瀉、腹部左側的疼痛、尿急和後急後勁(即便排空也需要排便的感覺)。3

In the two clinical studies on which the approval of UCERIS rectal aerosol foam was based, a significantly higher proportion of patients in the UCERIS group than in the placebo group were in remission at Week 6 (38.3% and 44.0% vs. 25.8% and 22.4% respectively, pooled p<0.0001) and had a rectal bleeding sub-score of 0 at Week 6 (46.6% and 50.0% vs. 28.0% and 28.6% respectively, pooled p<0.0001). There was also a higher proportion of patients in the UCERIS group than in the placebo group with an endoscopy sub-score of 0 or 1 at Week 6 (55.6% and 56.0% vs. 43.2% and 36.7% respectively.1

在批准UCERIS直腸氣溶膠泡沫所依據的兩項臨床研究中,UCERIS組中在第6周緩解的患者比例明顯高於安慰劑組(38.3%和44.0%,分別對25.8%和22.4%,合併p1

About Bausch Health
Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health outcomes. We develop, manufacture and market a range of products, primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals, and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, healthcare professionals, employees and investors. For more information, visit www.bauschhealth.com and connect with us on Twitter and LinkedIn.

關於 Bausch 健康
Bausch Health Companies Inc.(紐約證券交易所股票代碼:BHC)是一家全球多元化製藥公司,通過不懈努力提供更好的健康結果,豐富生活。我們通過在Bausch + Lomb的控股權開發、製造和銷售一系列產品,主要涉及胃腸病學、肝病學、神經病學、皮膚科、醫學美容設備、國際藥品和眼部健康。我們的目標是成爲一家全球綜合醫療保健公司,受到患者、醫療保健專業人員、員工和投資者的信任和重視。欲了解更多信息,請訪問 www.bauschhealth.com 然後通過以下方式聯繫我們 推特領英

The Bausch Health Canadian prescription treatment portfolio is focused on dermatology, gastrointestinal and cardio-metabolic conditions. Bausch Health also has two manufacturing facilities for prescription pharmaceuticals in Canada: in Laval, Quebec, and Steinbach, Manitoba. More information can be found at the Company's website at www.bauschhealth.ca.

Bausch Health 加拿大處方治療產品組合側重於皮膚科、胃腸道和心臟代謝疾病。Bausch Health還在加拿大擁有兩家處方藥生產設施:位於魁北克省拉瓦爾和曼尼托巴省的斯坦巴赫。更多信息可以在公司的網站上找到 www.bauschhealth.ca

References
1 Bausch Health, Canada Inc., UCERIS rectal foam Product Monograph, https://bauschhealth.ca/wp- content/uploads/2022/06/Uceris-PM-E-2020-04-15.pdf.
2 Gross V, et al, Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis, Aliment Pharmacol Ther. 2006;23(2):303-312.
3 IBD Clinic, University of Alberta: http://www.ibdclinic.ca/what-is-ibd/ulcerative-colitis/.

參考文獻
1 Bausch Health, Canada Inc.,UCERIS 直腸泡沫產品專著, https://bauschhealth.ca/wp- content/uploads/2022/06/Uceris-PM-E-2020-04-15.pdf。
2 Gross V 等人,布地奈德泡沫與布地奈德灌腸在活動性潰瘍性直腸炎和直腸乙狀結腸炎中的對比 Aliment Pharmacol. 2006; 23 (2): 303-312。
3 艾伯塔大學 IBD 診所: http://www.ibdclinic.ca/what-is-ibd/ulcerative-colitis/。

Investor Contact: Media Contact:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642 (toll-free)
Kevin Wiggins
corporate.communications@bauschhealth.com
(908) 541-3785
投資者聯繫人: 媒體聯繫人:
Garen Sarafian
ir@bauschhealth.com
(877) 281-6642(免費電話)
凱文威金斯
corporate.communications@bauschhealth.com
(908) 541-3785

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論